Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological Treatment of Parkinson’s Disease
Insha Zahoor, Amrina Shafi, Ehtishamul Haq
Codon Publications eBooks (2018), pp. 129-144
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Neuromicrobiology, an emerging neurometabolic facet of the gut microbiome?
Saba Miri, JuDong Yeo, Sarah Abubaker, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 76
Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson’s disease
Akshay Bandiwadekar, Jobin Jose, Gopika Gopan, et al.
Drug Delivery and Translational Research (2024)
Closed Access | Times Cited: 9
Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology
Joanna Wilson, Lisa Alcock, Alison J. Yarnall, et al.
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 66
Network metrics, structural dynamics and density functional theory calculations identified a novel Ursodeoxycholic Acid derivative against therapeutic target Parkin for Parkinson's disease
Aniket Naha, Sanjukta Banerjee, Reetika Debroy, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 4271-4287
Open Access | Times Cited: 29
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
Stuart Isaacson, Robert A. Hauser, Rajesh Pahwa, et al.
Clinical Parkinsonism & Related Disorders (2023) Vol. 9, pp. 100212-100212
Open Access | Times Cited: 18
The promising shadow of microbubble over medical sciences: from fighting wide scope of prevalence disease to cancer eradication
Ali Jangjou, Amir Hossein Meisami, Kazem Jamali, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 39
Tricompartmental Microcarriers with Controlled Release for Efficient Management of Parkinson’s Disease
N.M. Gupta, Pankaj Kumar Sharma, Shreyash Santosh Yadav, et al.
ACS Biomaterials Science & Engineering (2024) Vol. 10, Iss. 8, pp. 5039-5056
Closed Access | Times Cited: 5
The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease
Pedro Chaná‐Cuevas, Philippe Salles-Gándara, Alejandro Rojas‐Fernández, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 37
Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease
Maho Kubota, Nahoko Kobayashi, Toshifumi Sugizaki, et al.
PLoS ONE (2020) Vol. 15, Iss. 10, pp. e0240448-e0240448
Open Access | Times Cited: 37
The Impact of Exercise Intervention with Rhythmic Auditory Stimulation to Improve Gait and Mobility in Parkinson Disease: An Umbrella Review
Roberta Forte, Nicoletta Tocci, Giuseppe De Vito
Brain Sciences (2021) Vol. 11, Iss. 6, pp. 685-685
Open Access | Times Cited: 31
A Review of Genetic and Gene Therapy for Parkinson’s Disease
Omkar Dumbhare, Sagar S Gaurkar
Cureus (2023)
Open Access | Times Cited: 11
The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases
Lian Jin, L. S. Nie, Yan Deng, et al.
Cell Proliferation (2025)
Open Access
Evaluating the Impact of Adding Lee Silverman Voice Treatment BIG into Routine Physiotherapy on Both Motor and Nonmotor Functions in Individuals with Parkinson’s Disease
Zahra Sadaghiani, Nahid Tahan, Soheila Ganjeh, et al.
Dubai Medical Journal (2025) Vol. 8, Iss. 1, pp. 12-22
Open Access
Lipid nanocarrier of selegiline augmented anti-Parkinson’s effect via P-gp modulation using quercetin
Zufika Qamar, Muhammad Usama Ashhar, Annu, et al.
International Journal of Pharmaceutics (2021) Vol. 609, pp. 121131-121131
Closed Access | Times Cited: 25
Parkinson's disease: Are gut microbes involved?
Abass Olawale Omotosho, Yusuf Amuda Tajudeen, Habeebullah Jayeola Oladipo, et al.
Brain and Behavior (2023) Vol. 13, Iss. 8
Open Access | Times Cited: 10
A comprehensive examination of the evidence for whole of diet patterns in Parkinson's disease: a scoping review
Joanna Rees, Jillian Ryan, Manja Laws, et al.
Nutritional Neuroscience (2023) Vol. 27, Iss. 6, pp. 547-565
Open Access | Times Cited: 10
Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?
Alessia Furgiuele, Frederico C. Pereira, Stefano De Martini, et al.
Clinical & Translational Immunology (2023) Vol. 12, Iss. 10
Open Access | Times Cited: 9
Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease
Sasivimol Virameteekul, Andrew J. Lees, Roongroj Bhidayasiri
Movement Disorders (2024) Vol. 39, Iss. 11, pp. 1922-1937
Open Access | Times Cited: 3
Neuroprotective effects of punicalagin and/or micronized zeolite clinoptilolite on manganese‐induced Parkinson's disease in a rat model: Involvement of multiple pathways
Karema Abu‐Elfotuh, Ashwaq N. Abbas, Mazin A. A. Najm, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 10
Open Access | Times Cited: 3
Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s disease
Atul Kabra, Uttam Singh Baghel, Christophe Hano, et al.
Journal of Ayurveda and Integrative Medicine (2020) Vol. 11, Iss. 4, pp. 448-454
Open Access | Times Cited: 25
Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia
Valeria Calabrese, Anna Maio, Gioia Marino, et al.
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 24
Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review
Mahima Koshatwar, Sourya Acharya, Roshan Prasad, et al.
Cureus (2023)
Open Access | Times Cited: 8
Prevalence of radicular neuropathic pain in idiopathic Parkinson’s disease: A systematic review and meta-analysis
Leonardo Gomes Pereira, Patrícia Rodrigues, Fernanda Tibolla Viero, et al.
Ageing Research Reviews (2024) Vol. 99, pp. 102374-102374
Closed Access | Times Cited: 2
The Impact of the Blood–Brain Barrier and Its Dysfunction in Parkinson’s Disease: Contributions to Pathogenesis and Progression
Muhammad Khalid Iqbal, Bakhtawar Khan, Hifsa Hifsa, et al.
ACS Omega (2024) Vol. 9, Iss. 46, pp. 45663-45672
Open Access | Times Cited: 2
Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure
Savvas Dimiou, Rui M. Lopes, Ilona Kubajewska, et al.
International Journal of Pharmaceutics (2022) Vol. 618, pp. 121658-121658
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top